CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease

Author's Avatar
Apr 29, 2020
Article's Main Image

CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Single and Double-Digit Royalties, From the Sales of Arimoclomol

PR Newswire